Highlights and Quick Summary
- Stock Based Compensation for the quarter ending September 30, 2022 was $32.5 Thousand (a 72.87% increase compared to previous quarter)
- Year-over-year quarterly Stock Based Compensation decreased by -84.3%
- Annual Stock Based Compensation for 2021 was $207 Thousand (a 316.5% increase from previous year)
- Twelve month Stock Based Compensation ending September 30, 2022 was $411 Thousand
Trailing Stock Based Compensation for the last four month:
| 30 Sep '22 | — | — | — |
|---|---|---|---|
| $411 Thousand | — | — | — |
Visit stockrow.com/BBLG
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Stock Based Compensation of Bone Biologics Corp.
Most recent Stock Based Compensationof BBLG including historical data for past 10 years.Interactive Chart of Stock Based Compensation of Bone Biologics Corp.
Bone Biologics Corp. Stock Based Compensation for the past 10 Years (both Annual and Quarterly)
(All values are in $ million)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2022 | – | $0.03 | $0.02 | $0.15 | – |
| 2021 | – | – | – | $0.21 | $0.21 |
| 2019 | – | – | – | – | $0.05 |
Business Profile of Bone Biologics Corp.
Sector: Healthcare
Industry: Medical Devices